Cefixime Clinical Trial

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of Southern California
Study ID
NCT04958122
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cefixime 400mg — DRUG
    Oral cefixime 400 mg, one capsule, twice a day for 10 days
  • benzathine penicillin — DRUG
    Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU

Study Details

This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.

Key Dates

Start date
Jun 20, 2021
Status verified
Apr 2026
Primary completion
Jan 1, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cefixime
    Oral cefixime 400mg, taken twice a day for 10 days
  • Active Comparator: Benzathine Penicillin G
    Single intramuscular injection of 2.4 million units of benzathine penicillin G

Primary Outcome Measure

Response to treatment [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Southern CaliforniaLos AngelesCalifornia90032
Jeffrey D Klausner, MD
[email protected]
(415) 876-8901

Find similar trials in Los Angeles, CA

By condition
HIV
By specialty
Infectious disease
By research site
University of Southern California· Los Angeles, CA

Related Studies